{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:40:49Z","timestamp":1794368449276,"version":"4.9.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1097\/md.0000000000007213","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T10:23:45Z","timestamp":1498040625000},"page":"e7213","source":"Crossref","is-referenced-by-count":22,"title":["Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes"],"prefix":"10.1097","volume":"96","author":[{"given":"Hyouk-Jun","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-40-20210226","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00125-016-3899-2","article-title":"Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism","volume":"59","author":"Ahren","year":"2016","journal-title":"Diabetologia"},{"key":"R2-40-20210226","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-015-0294-0","article-title":"Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes","volume":"14","author":"Fisman","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"R3-40-20210226","first-page":"459821","article-title":"The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus","volume":"2013","author":"Yousefzadeh","year":"2013","journal-title":"J Diab Res"},{"key":"R4-40-20210226","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ejhf.90","article-title":"Heart failure and dipeptidyl peptidase-4 inhibitors","volume":"16","author":"Krum","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R5-40-20210226","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR\u2014TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"R6-40-20210226","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"R7-40-20210226","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in Type 2 diabetes mellitus: secondary analysis of a randomized clinical trial","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R8-40-20210226","doi-asserted-by":"crossref","first-page":"e0124287","DOI":"10.1371\/journal.pone.0124287","article-title":"Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study","volume":"10","author":"Seong","year":"2015","journal-title":"PloS ONE"},{"key":"R9-40-20210226","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jchf.2014.04.005","article-title":"Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study","volume":"2","author":"Weir","year":"2014","journal-title":"JACC Heart Fail"},{"key":"R10-40-20210226","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2014.12.029","article-title":"Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study","volume":"181","author":"Chen","year":"2015","journal-title":"Int J Cardiol"},{"key":"R11-40-20210226","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2014.09.038","article-title":"Sitagliptin and the risk of hospitalization for heart failure: a population-based study","volume":"177","author":"Wang","year":"2014","journal-title":"Int J Cardiol"},{"key":"R12-40-20210226","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2337\/dc14-1459","article-title":"Incretin-based drugs and the risk of congestive heart failure","volume":"38","author":"Yu","year":"2015","journal-title":"Diab Care"},{"key":"R13-40-20210226","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M15-0308","article-title":"Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with Type 2 diabetes mellitus","volume":"163","author":"Ou","year":"2015","journal-title":"Ann Intern Med"},{"key":"R14-40-20210226","doi-asserted-by":"crossref","first-page":"e0131122","DOI":"10.1371\/journal.pone.0131122","article-title":"Cardiovascular outcomes of sitagliptin in type 2 diabetic patients with acute myocardial infarction, a population-based cohort study in Taiwan","volume":"10","author":"Wang","year":"2015","journal-title":"PloS ONE"},{"key":"R15-40-20210226","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcjd.2015.02.002","article-title":"The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death","volume":"39","author":"Yu","year":"2015","journal-title":"Can J Diab"},{"key":"R16-40-20210226","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc15-0764","article-title":"Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with Type 2 diabetes: An observational study","volume":"39","author":"Fu","year":"2016","journal-title":"Diabetes Care"},{"key":"R17-40-20210226","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","article-title":"A multicenter observational study of incretin-based drugs and heart failure","volume":"374","author":"Filion","year":"2016","journal-title":"N Engl J Med"},{"key":"R18-40-20210226","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijcard.2016.02.146","article-title":"Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials","volume":"211","author":"Kongwatcharapong","year":"2016","journal-title":"Int J Cardiol"},{"key":"R19-40-20210226","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/TCRM.S105285","article-title":"The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study","volume":"12","author":"Shin","year":"2016","journal-title":"Therap Clin Risk Manag"},{"key":"R20-40-20210226","first-page":"101","article-title":"Pancreatic cancer is associated with impaired glucose metabolism","volume":"159","author":"Permert","year":"1993","journal-title":"Eur J Surg = Acta Chir"},{"key":"R21-40-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-2-4","article-title":"The relationship between diabetes and pancreatic cancer","volume":"2","author":"Wang","year":"2003","journal-title":"Mol Cancer"},{"key":"R22-40-20210226","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R23-40-20210226","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R24-40-20210226","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/2042098615623915","article-title":"Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications","volume":"7","author":"Karagiannis","year":"2016","journal-title":"Therap Adv Drug Saf"},{"key":"R25-40-20210226","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/heartjnl-2016-309687","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure","volume":"103","author":"Ou","year":"2017","journal-title":"Heart"},{"key":"R26-40-20210226","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.clinthera.2014.10.009","article-title":"Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?","volume":"36","author":"Clifton","year":"2014","journal-title":"Clin Therap"},{"key":"R27-40-20210226","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"key":"R28-40-20210226","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/HYPERTENSIONAHA.113.02767","article-title":"Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition","volume":"63","author":"Devin","year":"2014","journal-title":"Hypertension"},{"key":"R29-40-20210226","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular biology of the incretin system","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr Rev"},{"key":"R30-40-20210226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1475-2840-13-43","article-title":"Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats","volume":"13","author":"Miyoshi","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"R31-40-20210226","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00380-015-0724-7","article-title":"Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes","volume":"31","author":"Hashikata","year":"2016","journal-title":"Heart Vessels"},{"key":"R32-40-20210226","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1152\/ajpendo.00553.2014","article-title":"DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-kappaB activation","volume":"309","author":"Shinjo","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R33-40-20210226","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bbadis.2014.06.004","article-title":"Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2","volume":"1842","author":"Wronkowitz","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"R34-40-20210226","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2337\/dc10-0187","article-title":"The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha","volume":"33","author":"Fadini","year":"2010","journal-title":"Diabetes Care"},{"key":"R35-40-20210226","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/dom.12197","article-title":"All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population","volume":"16","author":"Scheller","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R36-40-20210226","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4093\/dmj.2015.39.3.247","article-title":"Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean health insurance claims database","volume":"39","author":"Suh","year":"2015","journal-title":"Diab Metab J"},{"key":"R37-40-20210226","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2337\/diacare.19.8.849","article-title":"A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group","volume":"19","author":"Goldberg","year":"1996","journal-title":"Diab Care"},{"key":"R38-40-20210226","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1161\/01.CIR.103.25.3111","article-title":"Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide","volume":"103","author":"Mocanu","year":"2001","journal-title":"Circulation"},{"key":"R39-40-20210226","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/VHRM.S33194","article-title":"Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]","volume":"8","author":"Basit","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"R40-40-20210226","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1479164112475102","article-title":"Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial","volume":"10","author":"Rosenstock","year":"2013","journal-title":"Diab Vasc Dis Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:52:32Z","timestamp":1620960752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201706230-00040"}},"subtitle":["A retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":40,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007213","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}